159 related articles for article (PubMed ID: 37615812)
1. Predicting [
Siebinga H; de Wit-van der Veen BJ; Beijnen JH; Stokkel MPM; Dorlo TPC; Huitema ADR; Hendrikx JJMA
EJNMMI Phys; 2023 Aug; 10(1):48. PubMed ID: 37615812
[TBL] [Abstract][Full Text] [Related]
2. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [
Siebinga H; Hendrikx JJMA; de Vries-Huizing DMV; Huitema ADR; de Wit-van der Veen BJ
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):820-827. PubMed ID: 37843598
[TBL] [Abstract][Full Text] [Related]
3. A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in
Plachouris D; Eleftheriadis V; Nanos T; Papathanasiou N; Sarrut D; Papadimitroulas P; Savvidis G; Vergnaud L; Salvadori J; Imperiale A; Visvikis D; Hazle JD; Kagadis GC
Med Phys; 2023 Nov; 50(11):7222-7235. PubMed ID: 37722718
[TBL] [Abstract][Full Text] [Related]
4. A physiologically based pharmacokinetic model for [
Siebinga H; de Wit-van der Veen BJ; Beijnen JH; Dorlo TPC; Huitema ADR; Hendrikx JJMA
EJNMMI Res; 2023 Feb; 13(1):8. PubMed ID: 36735114
[TBL] [Abstract][Full Text] [Related]
5. Quantification of biochemical PSA dynamics after radioligand therapy with [
Siebinga H; de Wit-van der Veen BJ; de Vries-Huizing DMV; Vogel WV; Hendrikx JJMA; Huitema ADR
EJNMMI Phys; 2024 Apr; 11(1):39. PubMed ID: 38656678
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor saturation after administration of high peptide amounts of [
Siebinga H; Veerman CHAM; de Wit-van der Veen L; Stokkel MPM; Hendrikx JJMA; Aalbersberg EA
EJNMMI Res; 2022 Dec; 12(1):74. PubMed ID: 36515683
[TBL] [Abstract][Full Text] [Related]
7. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
[TBL] [Abstract][Full Text] [Related]
8. Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE.
Schottelius M; Šimeček J; Hoffmann F; Willibald M; Schwaiger M; Wester HJ
EJNMMI Res; 2015; 5():22. PubMed ID: 25918675
[TBL] [Abstract][Full Text] [Related]
9. [
Pauwels E; Dekervel J; Verslype C; Clement PM; Dooms C; Baete K; Goffin K; Jentjens S; Van Laere K; Van Cutsem E; Deroose CM
Am J Nucl Med Mol Imaging; 2022; 12(5):152-162. PubMed ID: 36419585
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
11. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers.
Peterson AB; Wang C; Wong KK; Frey KA; Muzik O; Schipper MJ; Dewaraja YK
Clin Nucl Med; 2023 May; 48(5):393-399. PubMed ID: 37010563
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
14. Initial clinical evaluation of indigenous
Parghane RV; Mitra A; Bannore TU; Rakshit S; Banerjee S; Basu S
World J Nucl Med; 2021; 20(1):73-81. PubMed ID: 33850492
[No Abstract] [Full Text] [Related]
15. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
16. Prediction of
Lee H; Kipnis ST; Niman R; O'Brien SR; Eads JR; Katona BW; Pryma DA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201627
[TBL] [Abstract][Full Text] [Related]
17. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637144
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of
Siebinga H; Privé BM; Peters SMB; Nagarajah J; Dorlo TPC; Huitema ADR; de Wit-van der Veen BJ; Hendrikx JJMA
CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1060-1071. PubMed ID: 36760133
[TBL] [Abstract][Full Text] [Related]
19. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
[TBL] [Abstract][Full Text] [Related]
20. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
